When the Securities and Exchange Commission began investigating an investment fund for suspected insider trading, Haynes and Boone investigated the allegations and walked the fund and its analysts through document production and testimony. Haynes and Boone ultimately persuaded the SEC that the fund's short position in pharmaceutical stocks was based on market and industry analysis and not inside information. The SEC closed its investigation without taking any enforcement action.